FOXO4-DRI significantly improves vascular function and delays vascular aging
Medically-supervised GLP-1 treatment offers a non-surgical, highly effective alternative at a much more accessible price point
Best practice reminders Consistency is key: For best results, consistent daily use is recommended
46 That dedicated kidney outcomes study, involving over 3500 patients with both T2D and established chronic kidney disease, demonstrated that once-weekly subcutaneous semaglutide 1.0 mg significantly reduced the primary composite renal outcome (including kidney failure onset, a 50% persistent decline in estimated glomerular filtration rate (eGFR), or renal/cardiovascular death) compared with placebo
Plus, read personalized recommendations for each from our Director of Education, Rosalba Martone, so you can see maximum results before your eyes